Two Sigma Advisers’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-192,800
| Closed | -$2.49M | – | 1446 |
|
|
2025
Q4 | $2.49M | Buy |
192,800
+149,800
| +348% | +$1.92M | ﹤0.01% | 1092 |
|
|
2025
Q3 | $556K | Sell |
43,000
-146,500
| -77% | -$1.96M | ﹤0.01% | 1722 |
|
|
2025
Q2 | $3.37M | Sell |
189,500
-251,900
| -57% | -$4.39M | 0.01% | 889 |
|
|
2025
Q1 | $7.87M | Sell |
441,400
-144,600
| -25% | -$3.28M | 0.02% | 611 |
|
|
2024
Q4 | $17.5M | Sell |
586,000
-377,900
| -39% | -$8M | 0.04% | 353 |
|
|
2024
Q3 | $15.1M | Sell |
963,900
-355,500
| -27% | -$6.45M | 0.04% | 381 |
|
|
2024
Q2 | $22.6M | Sell |
1,319,400
-119,500
| -8% | -$2.1M | 0.05% | 305 |
|
|
2024
Q1 | $22.5M | Sell |
1,438,900
-195,600
| -12% | -$2.88M | 0.05% | 317 |
|
|
2023
Q4 | $24.4M | Buy |
1,634,500
+712,100
| +77% | +$9.53M | 0.06% | 289 |
|
|
2023
Q3 | $14.9M | Buy |
922,400
+851,800
| +1,207% | +$24.6M | 0.04% | 368 |
|
|
2023
Q2 | $2.93M | Buy |
70,600
+14,500
| +26% | +$900K | 0.01% | 1003 |
|
|
2023
Q1 | $3.37M | Sell |
56,100
-85,800
| -60% | -$6.86M | 0.01% | 995 |
|
|
2022
Q4 | $10.4M | Sell |
141,900
-39,900
| -22% | -$3M | 0.03% | 498 |
|
|
2022
Q3 | $13.8M | Sell |
181,800
-29,300
| -14% | -$2.29M | 0.04% | 410 |
|
|
2022
Q2 | $14.7M | Sell |
211,100
-57,200
| -21% | -$4.31M | 0.04% | 396 |
|
|
2022
Q1 | $22.2M | Sell |
268,300
-34,900
| -12% | -$2.57M | 0.06% | 300 |
|
|
2021
Q4 | $22.8M | Sell |
303,200
-23,500
| -7% | -$2.36M | 0.06% | 282 |
|
|
2021
Q3 | $38M | Buy |
326,700
+11,400
| +4% | +$1.72M | 0.1% | 206 |
|
|
2021
Q2 | $69.9M | Sell |
315,300
-136,600
| -30% | -$26.6M | 0.18% | 110 |
|
|
2021
Q1 | $59.7M | Sell |
451,900
-29,000
| -6% | -$4.59M | 0.16% | 129 |
|
|
2020
Q4 | $83.2M | Sell |
480,900
-172,800
| -26% | -$23.6M | 0.22% | 101 |
|
|
2020
Q3 | $72.8M | Sell |
653,700
-231,800
| -26% | -$18.5M | 0.21% | 110 |
|
|
2020
Q2 | $52.5M | Buy |
885,500
+262,100
| +42% | +$17.2M | 0.15% | 143 |
|
|
2020
Q1 | $42M | Sell |
623,400
-269,900
| -30% | -$21.3M | 0.16% | 144 |
|
|
2019
Q4 | $75.3M | Sell |
893,300
-1,200
| -0.1% | -$96.9K | 0.17% | 138 |
|
|
2019
Q3 | $66.9M | Buy |
894,500
+282,200
| +46% | +$22.6M | 0.16% | 151 |
|
|
2019
Q2 | $38.7M | Buy |
612,300
+81,000
| +15% | +$4.1M | 0.1% | 249 |
|
|
2019
Q1 | $25.6M | Buy |
531,300
+285,800
| +116% | +$13.8M | 0.06% | 345 |
|
|
2018
Q4 | $8.22M | Sell |
245,500
-117,300
| -32% | -$4.29M | 0.02% | 627 |
|
|
2018
Q3 | $19M | Buy |
362,800
+116,300
| +47% | +$4.63M | 0.05% | 404 |
|
|
2018
Q2 | $7.71M | Buy |
246,500
+215,300
| +690% | +$5.99M | 0.02% | 670 |
|
|
2018
Q1 | $680K | Buy |
31,200
+20,751
| +199% | +$446K | ﹤0.01% | 1709 |
|
|
2017
Q4 | $211K | Buy |
+10,449
| New | +$201K | ﹤0.01% | 2076 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
Two Sigma Advisers's NVCR Position: Q1 2026 in Review
Two Sigma Advisers sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 192,800 shares — an estimated $2.49M sold.
Two Sigma Advisers first reported a position in NVCR in Q4 2017 and held it in 33 quarters. The position peaked at $83.2M in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- Two Sigma Advisers reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
- Two Sigma Advisers sold 192,800 NovoCure shares in Q1 2026, an estimated $2.49M.
- Two Sigma Advisers first reported a position in NovoCure in Q4 2017 and held it in 33 quarters.
- Two Sigma Advisers's NovoCure position peaked at $83.2M in Q4 2020.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on Two Sigma Advisers's 13F filing for Q1 2026.